MGC Pharma

APRIL 4, 2018

A word from Ron Lipsky, Manager of Business Development and International Relations at MGC Pharmaceuticals. CBD-based treatment for people with Refractory Epilepsy?—?is Refractory Epilepsy is epilepsy that involves frequent and severe seizures that are difficult to treat. CannEpil™?—?CBD-based

Epilepsy 100

Epilepsy Pharmaceutical Research and Development CBD 100

Cannabis Law Report

JANUARY 15, 2019

British firm GW Pharmaceuticals is licking its wounds after US judges tossed out its attempt to patent multiple cannabinoids for epilepsy treatment following an eight-year battle. The patent, which has been embroiled in dispute since 2010, is for “the use of one or more cannabinoids in the treatment of epilepsy”.

Epilepsy 71

Epilepsy Cannabinoids Treatment Research and Development 71

Cannabis Law Report

DECEMBER 23, 2021

DUBLIN–(BUSINESS WIRE)– “The Pharmaceutical Cannabis Report: 2nd Edition” report has been added to ResearchAndMarkets.com’s offering. In both Europe and the United States, the sales of unapproved cannabis products such as smokable flower and full spectrum oils dwarf those of approved pharmaceuticals.

Pharmaceutical 74

Pharmaceutical Clinical Trials Research and Development Cannabinoids 74

Cannabis Law Report

SEPTEMBER 9, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, will present at the H.C. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 74

Pharmaceutical Clinical Trials Chronic Pain Epilepsy 74

Cannabis Law Report

JULY 12, 2019

This differs sharply from the conventional course of cannabis medicine, which is to use whole, clean plant extracts to treat epilepsy and to gradually discontinue use of conventional pharmaceuticals. An Israeli study of cannabis versus epilepsy, however, used natural extracts with a ratio of 20:1 CBD:THC.

Extraction 73

Extraction Pharmaceutical CBD Epilepsy 73

WeedAdvisor

SEPTEMBER 24, 2019

GW Pharmaceuticals created the medication after studies showed surprising success treating severe childhood epilepsy, specifically Lennox-Gastaut Syndrome and Dravet Syndrome. The post Epidiolex CBD Epilepsy Drug Receives Approval in Europe appeared first on WeedAdvisor. On June 25, 2018, the U.S. In the U.S.,

Epilepsy 49

Epilepsy CBD Pharmaceutical Access 49

Cannabis Law Report

AUGUST 24, 2021

BALTIMORE–(BUSINESS WIRE)– $MYMD — MyMD Pharmaceuticals, Inc. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy.

Pharmaceutical 75

Pharmaceutical Clinical Trials Chronic Pain CBD 75

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. What about other medical cannabis products? What do experts say? September 23, 2019.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

AUGUST 17, 2021

–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. We look forward to initiating our Phase 3 trial and adding to the body of evidence that supports ganaxolone’s potential as an innovative treatment option for rare epilepsies.”. About Marinus Pharmaceuticals. Marinus Pharmaceuticals, Inc.

Pharmaceutical 76

Pharmaceutical Clinical Trials Treatment Patients 76

Cannabis Law Report

DECEMBER 3, 2021

.–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. Chief Executive Officer of Marinus Pharmaceuticals. “We Phase 2, Placebo-Controlled Clinical Study of Oral Ganaxolone in PCDH19-Clustering Epilepsy (the Violet Study). About Marinus Pharmaceuticals. Marinus Pharmaceuticals, Inc.

Epilepsy 40

Epilepsy Pharmaceutical Data Clinical Trials 40

Otherside Farms

JANUARY 24, 2019

Federal regulators have approved two clinical studies testing whether a marijuana-based epilepsy drug may help prevent seizures among epileptic children. Source: FDA Approves Marijuana-Based Epilepsy Drug For Use On Kids In Clinical Trials. Although both studies will enroll 25 patients initially, the U.S. In the upcoming U.S.

Clinical Trials 45

Clinical Trials Epilepsy Marijuana Pharmaceutical 45

Cannabis Law Report

JULY 30, 2019

Following an encouraging initial US launch, GW Pharmaceuticals’s cannabidiol oral solution is also set to achieve European approval later in 2019. The US approval of Zogenix’s Fintepla, a potential competitor for GW’s drug, has been delayed but still lo… The European Pharmaceutical Review reports.

Epilepsy 40

Epilepsy Pharmaceutical Medicine Treatment 40

Cannabis Law Report

SEPTEMBER 28, 2021

DUBLIN–(BUSINESS WIRE)–The “Epilepsy – Pipeline Insight, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering. This Epilepsy – Pipeline Insight, 2021 provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Epilepsy pipeline landscape.

Epilepsy 40

Epilepsy Clinical Trials Research and Development Pharmaceutical 40

Cannabis Law Report

SEPTEMBER 29, 2022

Australia’s drugs regulator issues 73 infringement notices over claims prescriptions could treat conditions such as cancer and epilepsy. The Therapeutic Goods Administration (TGA) issued 73 infringement notices totalling $972,360 between the medicinal cannabis companies MGC Pharmaceuticals Ltd, Cannatrek Ltd and Little Green Pharma Ltd.

Epilepsy 52

Epilepsy Conditions Media Medicine 52

Cannabis Law Report

JULY 2, 2021

Dr. Rungpetch Sakulbumrungsilp Dean of the Faculty of Pharmaceutical Sciences, Chulalongkorn University. Dr. Rungpetch Sakulbumrungsilp, Dean of the Faculty of Pharmaceutical Sciences, Chulalongkorn University, unlike the present in which many facets and aspects of cannabis are being studied in addition to the work of Chula C.A.N.S.,

Research and Development 105

Research and Development Pharmaceutical Extraction Seed-To-Sale 105

Cannabis Law Report

JUNE 5, 2019

Press Release: Thailand Government Pharmaceutical Organization. The Pharmaceutical Organization, Department of Medical Affairs, signed a joint research on standard quality medical marijuana extracts for patients with chemo-allergic cancer, epilepsy, muscle contraction in patients with deteriorating nerve sheaths. 30 May 2019.

Pharmaceutical 40

Pharmaceutical Extraction Epilepsy Research and Development 40

Cannabis Law Report

JULY 6, 2021

It appears most likely to be used for small children with severe myoclonic epilepsy, known as Dravet syndrome. According to the Epilepsy Foundation, Dravet syndome is rare, drug-resistant and leads to prolonged seizures. He said the department had a pharmaceutical products tendering process every two years.

Medicine 81

Medicine Epilepsy Pharmaceutical Access 81

MassRoots

JANUARY 10, 2019

Lawmakers have been listening to constituents suffering from debilitating diseases, like epilepsy and cancer, who say they would like to have the option to explore how medical cannabis may ease their symptoms. Cassie Everett, a woman from Louisville who suffers from epilepsy contacted Rep. Why Medical Marijuana?

Legalization 111

Legalization Marijuana Epilepsy Legislation 111

MGC Pharma

DECEMBER 12, 2017

A word from Elad Segev, Manager of Breeding and Cultivation at MGC Pharmaceuticals. It’s also effective in treating patients with refractory epilepsy who experience daily seizures. In fact, MGC Pharma has just released their first product, CannEpil™, a CBD-based medication to help treat patients with refractory epilepsy.

Epilepsy 100

Epilepsy Pharmaceutical Cannabinoids THC 100

Peninsula Alternative Health

MAY 15, 2019

Epilepsy Seizure disorders are on the list of qualifying conditions for most medical cannabis states. Because nearly one-third of patients with epilepsy are not getting the results they want from conventional treatments, they are eager to experiment with natural cannabinoid therapy. References Staff, T.

Conditions 89

Conditions Therapy Cannabinoids Epilepsy 89

Veriheal

SEPTEMBER 16, 2020

Epidiolex is the sole cannabis-derived pharmaceutical that has been approved by the FDA – although it is worth noting that the organization has also approved three synthetic cannabis-related products. Though these tumors are noncancerous in nature, their presence can cause health problems, including epilepsy. What is Epidiolex?

Access 98

Access Epilepsy Treatment Conditions 98

MMJ Recs

NOVEMBER 20, 2023

Epilepsy Management: CBD, in particular, has emerged as an effective treatment for epilepsy, especially in individuals with rare and severe forms of the condition. For example, the discovery of CBD’s effectiveness in managing epilepsy led to the development of Epidiolex, the first FDA-approved medication derived from marijuana.

Cannabinoids 98

Cannabinoids Epilepsy Treatment Marijuana 98

The Cannigma

JUNE 1, 2021

Patients can take part if they have a medical condition which has not responded to pharmaceutical drugs. Some of the qualifying health conditions include epilepsy, neuropathic pain, chemotherapy side effects, a need for palliative care, and pain linked to multiple sclerosis, according to France24.

Law 115

Law Epilepsy Programs Patients 115

Cannabis Life Network

JULY 24, 2019

GW Pharmaceuticals has been creating unusual blends of clinical cannabis for over two decades. Epidiolex is an abnormal, proprietary cannabidiol tincture that was developed for epilepsy. This clinical concoction has been under some well-deserved criticism for several reasons, such as a liver damage warning.

CBD 13

CBD Pharmaceutical Epilepsy Tincture 13

Cannabis Law Report

JANUARY 16, 2022

Malaysia’s National Pharmaceutical Regulatory Agency (NPRA) previously approved a prescription medicine derived from cannabis in 2014 to treat muscle spasms and spasticity from multiple sclerosis. Sativex was developed by GW Pharmaceuticals, a maker of cannabinoid therapeutics based in Ireland.

Pharmaceutical 98

Pharmaceutical Research and Development Epilepsy Medicine 98

Cannabis Law Report

NOVEMBER 5, 2019

Cabot Wealth Management Inc increased its stake in Gw Pharmaceuticals Plc (GWPH) by 34.2% The institutional investor held 20,865 shares of the major pharmaceuticals company at the end of 2019Q2, valued at $3.60M, up from 15,548 at the end of the previous reported quarter. based on its latest 2019Q2 regulatory filing with the SEC.

Pharmaceutical 45

Pharmaceutical Epilepsy Treatment Medicine 45

Cannabis Law Report

JULY 26, 2021

OTCQB: SPRCY), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced a number of updates regarding its Phase IIb clinical study in Tourette Syndrome using the proprietary cannabinoid-based treatment- SCI-110. About SciSparc (OTCQB: SPRCY): SciSparc Ltd.

Research and Development 105

Research and Development Supply Chain Pharmaceutical Treatment 105

Puff Puff Post

OCTOBER 3, 2019

Previous success from treating epilepsy with Cannabinoids now motivates doctors to investigate the plant’s effectiveness in treating symptoms of autism. Montefiore Medical Center in New York and GW Pharmaceuticals are examining the effects of a cannabis compound when administered to children on the autism spectrum.

Research and Development 94

Research and Development Epilepsy Clinical Trials Treatment 94

CannaTech

AUGUST 9, 2018

We are delighted to introduce you to some new friends set to make a big impact on the medical cannabis advocacy scene… the creators of a new documentary called Separating the Strains ; a deeply personal narrative that charts the reality of living with epilepsy, with and without cannabis medication as a treatment option.

Strains 69

Strains Epilepsy Advocacy Medicine 69

Project CBD

FEBRUARY 28, 2023

5 In June 2018, the FDA approved Epidiolex® (GW Pharmaceuticals; Cambridge, UK), the first FDA-approved pharmaceutical drug to contain a “purified drug substance [CBD] derived from marijuana,” for the treatment of seizures associated with two rare epilepsy disorders. Epilepsy Behav. Accessed October 17, 2022. 2021.108514.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

DECEMBER 1, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021. MyMD Pharmaceuticals, Inc.

Pharmaceutical 40

Pharmaceutical Clinical Trials Chronic Pain Therapy 40

Canna Law Blog

MARCH 12, 2019

9,066,920 – “Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy” (“the 920 Patent”). GW Pharma”) and Otsuka Pharmaceuticals Co., Epidiolex was approved to treat two rare forms of epilepsy: Dravet syndrome and Lennox-Gastaut syndrome. In this case, the subject patent was U.S.

Epilepsy 74

Epilepsy Pharmaceutical Cannabinoids CBD 74

MedicalJane

OCTOBER 3, 2019

The United States Department of Defense and GW Pharmaceuticals are collaborating on a new clinical trial at the Montefiore Medical Center in New York. The study examines the effect of the cannabinoid Cannabidivarin, more commonly referred to as CBDV , on irritability and repetitive behaviors in children with autism spectrum disorder.

Clinical Trials 74

Clinical Trials Epilepsy Pharmaceutical Treatment 74

Leafwell

MAY 5, 2021

When it comes to caring for diseases and the most vulnerable among us, there are some clear areas where modern pharmaceutical medicine fails, and where medical marijuana succeeds.

Chronic Pain 52

Chronic Pain Epilepsy Law Pharmaceutical 52

Cannabis Law Report

JANUARY 4, 2022

–(BUSINESS WIRE)– #pharma –Virpax ® Pharmaceuticals, Inc. About Virpax Pharmaceuticals. Virpax recently acquired global rights to VRP324, a product candidate for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of epilepsy in children (a rare pediatric disease) and adults.

Pharmaceutical 40

Pharmaceutical Research and Development Chronic Pain Events 40

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Enquiries: GW Pharmaceuticals plc.

Pharmaceutical 51

Pharmaceutical Clinical Trials Research and Development Programs 51

Cannabis Law Report

AUGUST 20, 2021

SLSG and its Swiss subsidiary, Savim SA , are developing specific proprietary strains of cannabis, with a focus on various areas, but particularly on future medical treatments for a variety of illnesses and diseases, including epilepsy, autism, and the different stages of COVID-19.

Research and Development 116

Research and Development Strains Treatment Epilepsy 116